Both IDO1 and – albeit less frequently – TDO are expressed in human tumors and appear to play a role in tumoral immune resistance, which warrants ongoing drug discovery efforts aimed at the clinical development of IDO and TDO inhibitors for cancer therapy. Here, IDO1 is linked to cancer.